

IMBRUVICA™

Ibrutinib (140 mg), capsules

Ibrutinib (140 mg, 280 mg, 420 mg) film-coated tablets

What is in this leaflet

1. What IMBRUVICA is used for
2. How IMBRUVICA works
3. Before you use IMBRUVICA
4. How to use IMBRUVICA
5. While you are using it
6. Side effects
7. Storage and Disposal of IMBRUVICA
8. Product Description
9. Manufacturer and Product Registration Holder
10. Date of revision

What IMBRUVICA is used for

IMBRUVICA is an anticancer medicine that contains the active substance ibrutinib. It belongs to a class of medicines called protein kinase inhibitors.

It is used to treat the following blood cancers in adults:

- Mantle Cell Lymphoma (MCL), a type of cancer affecting the lymph nodes.
- Chronic Lymphocytic Leukaemia (CLL) a type of cancer affecting white blood cells called lymphocyte that also involves the lymph nodes. IMBRUVICA is used in patients who have not previously been treated for CLL or when the disease has come back or has not responded to treatment.
- Waldenström's macroglobulinaemia (WM), a type of cancer affecting white blood cells called lymphocytes. It is used in patients who have not previously been treated for WM or when the disease has come back or has not responded to treatment or in patients for whom chemotherapy given together with an antibody is not a suitable therapy.
- IMBRUVICA is also used to treat chronic graft versus host disease, a condition in which transplanted cells from another person (the donor) attack the body (the host) causing organ damage.

How IMBRUVICA works

In MCL, CLL and WM, IMBRUVICA works by blocking Bruton's tyrosine kinase, a protein in

the body that helps these cancer cells grow and survive. By blocking this protein, IMBRUVICA helps kill and reduce the number of cancer cells. It also slows down the worsening of the cancer.

Before you use IMBRUVICA

- When you must not use it

Do not take IMBRUVICA

- if you are allergic to ibrutinib or any of the other ingredients of this medicine (listed in section "Ingredients")
- if you are taking a herbal medicine called St. John's Wort, used for depression. If you are not sure about this, talk to your doctor, pharmacist or nurse before taking this medicine.

Children and adolescents

IMBRUVICA should not be used in children and adolescents.

- Before you start to use it

Warnings and precautions

Talk to your doctor, pharmacist or nurse before taking IMBRUVICA:

- if you have ever had unusual bruising or bleeding or are on any medicines or supplements that increase your risk of bleeding (see section "Taking other medicines")
- if you have irregular heart beat or have a history of irregular heart beat or severe heart failure, or if you feel any of the following: shortness of breath, weakness, dizziness, light-headedness, fainting or near fainting, chest pain or swollen legs
- if you have liver problems, including if you ever had or now have a hepatitis B infection (a liver infection)
- if you have high blood pressure
- if you have recently had any surgery, especially if this might affect how you absorb food or medicines from your stomach or gut
- if you are planning to have any surgery – your doctor may ask you to stop taking IMBRUVICA

for a short time (3 to 7 days) before and after your surgery.

- if you have kidney problems.

If any of the above apply to you (or you are not sure), talk to your doctor, pharmacist or nurse before or while taking this medicine (see section **Side effects**).

When taking IMBRUVICA, tell your doctor immediately if you notice or someone notices in you: memory loss, trouble thinking, difficulty walking or sight loss – these may be due to a very rare but serious brain infection which can be fatal (Progressive Multifocal Leukoencephalopathy or PML).

Tell your doctor immediately if you notice or someone notices in you: sudden numbness or weakness in the limbs (especially on one side of the body), sudden confusion, trouble speaking or understanding speech, sight loss, difficulty walking, loss of balance or lack of coordination, sudden severe headache with no known cause. These may be signs and symptoms of stroke.

Tell your doctor immediately if you develop left upper belly (abdominal) pain, pain below the left rib cage or at the tip of your left shoulder (these may be symptoms of rupture of the spleen) after you stop taking IMBRUVICA.

Effects on the heart

Treatment with IMBRUVICA may affect the heart, especially if you already have heart diseases such as rhythm problems, heart failure, high blood pressure or have diabetes. The effects may be severe and could cause death, including sometimes sudden death. Your heart function will be checked before and during treatment with IMBRUVICA. Tell your doctor immediately if you feel breathless, have difficulty breathing when lying down, swelling of the feet, ankles or legs and weakness/tiredness during treatment with IMBRUVICA – these may be signs of heart failure.

IMBRUVICA™

Ibrutinib (140 mg), capsules

Ibrutinib (140 mg, 280 mg, 420 mg) film-coated tablets

You may experience viral, bacterial, or fungal infections during treatment with IMBRUVICA. Contact your doctor if you have fever, chills, weakness, confusion, body aches, cold or flu symptoms, feel tired or feel short of breath, yellowing of the skin or eyes (jaundice). These could be signs of an infection.

Haemophagocytic lymphohistiocytosis

There have been rare reports of excessive activation of white blood cells associated with inflammation (haemophagocytic lymphohistiocytosis), which can be fatal if not diagnosed and treated early. If you experience multiple symptoms such as fever, swollen glands, bruising, or skin rash, contact your doctor immediately.

- Taking other medicines

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines obtained without a prescription, herbal medicines and supplements. This is because IMBRUVICA may affect the way some other medicines work. Also some other medicines can affect the way IMBRUVICA works.

IMBRUVICA may make you bleed more easily. This means you should tell your doctor if you take other medicines that increase your risk of bleeding. This includes:

- acetyl salicylic acid and non-steroidal anti-inflammatories (NSAIDs) such as ibuprofen or naproxen
- blood thinners such as warfarin, heparin or other medicines for blood clots
- supplements that may increase your risk of bleeding such as fish oil, vitamin E or flaxseed.

If any of the above apply to you (or you are not sure), talk to your doctor, pharmacist or nurse before taking IMBRUVICA.

Also tell your doctor if you take any of the following medicines – The effects of IMBRUVICA or other medicines may be influenced if you take IMBRUVICA together with any of the following medicines:

- medicines called antibiotics to treat bacterial infections – clarithromycin, telithromycin, ciprofloxacin, erythromycin or rifampicin
- medicines for fungal infections – posaconazole, ketoconazole, itraconazole, fluconazole or voriconazole
- medicines for HIV infection – ritonavir, cobicistat, indinavir, nelfinavir, saquinavir, amprenavir, atazanavir or fosamprenavir
- medicines to prevent nausea and vomiting associated with chemotherapy – aprepitant
- medicines for depression – nefazodone
- medicines called kinase inhibitors for treatment of other cancers – crizotinib or imatinib
- medicines called calcium channel blockers for high blood pressure or chest pain – diltiazem or verapamil
- medicines called statins to treat high cholesterol – rosuvastatin
- heart medicines/anti-arrhythmics – amiodarone or dronedarone.
- medicines to prevent seizures or to treat epilepsy, or medicines to treat a painful condition of the face called trigeminal neuralgia – carbamazepine or phenytoin

If any of the above apply to you (or you are not sure), talk to your doctor, pharmacist or nurse before taking IMBRUVICA.

If you are taking digoxin, a medicine used for heart problems, or methotrexate, a medicine used to treat other cancers and to reduce the activity of the immune system (e.g. for rheumatoid arthritis or psoriasis), it should be taken at least 6 hours before or after IMBRUVICA.

How to use IMBRUVICA

- How much to use

Always take this medicine exactly as your doctor, pharmacist or nurse has told you. Check with your doctor, pharmacist or nurse if you are not sure.

Mantle Cell Lymphoma (MCL)

The recommended dose of IMBRUVICA is 560 mg once a day.

Chronic Lymphocytic Leukaemia (CLL) /Waldenström's macroglobulinaemia (WM)/ Chronic Graft Versus Host Disease (cGVHD)

The recommended dose of IMBRUVICA is 420 mg once a day.

Your doctor may adjust your dose.

- When to use it

- Take the capsules or tablets orally (by mouth) with a glass of water.
- Take the capsules or tablets about the same time each day.
- Swallow the capsules or tablets whole. Do not open, break or chew the capsules. Do not break or chew the tablets.

- How long to use it

Do not stop taking this medicine unless your doctor tells you.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

- If you forget to use it

- If you miss a dose, it can be taken as soon as possible on the same day with a return to the normal schedule the following day.
- Do not take a double dose to make up for a forgotten dose.
- If you are not sure, talk to your doctor, pharmacist or nurse about when to take your next dose.

- If you use too much (overdose)

If you take more IMBRUVICA than you should, talk to a doctor or go to a hospital straight away.

IMBRUVICA™

Ibrutinib (140 mg), capsules

Ibrutinib (140 mg, 280 mg, 420 mg) film-coated tablets

Take the capsules or tablets and this leaflet with you.

While you are using it

- Things you must do

Tests and check-ups before and during treatment

Tumour lysis syndrome (TLS):

Unusual levels of chemicals in the blood caused by the fast breakdown of cancer cells have happened during treatment of cancer and sometimes even without treatment. This may lead to changes in kidney function, abnormal heartbeat, or seizures. Your doctor or another healthcare provider may do blood tests to check for TLS.

Lymphocytosis: Laboratory tests may show an increase in white blood cells (called “lymphocytes”) in your blood in the first few weeks of treatment. This is expected and may last for a few months. This does not necessarily mean that your blood cancer is getting worse. Your doctor will check your blood counts before or during the treatment and in rare cases they may need to give you another medicine. Talk to your doctor about what your test results mean.

Events related to the liver: Your doctor will do some blood tests to check whether your liver is working properly or that you do not have a liver infection, known as viral hepatitis, or whether hepatitis B has become active again, which could be fatal.

- Things you must not do

Pregnancy, breast-feeding and fertility

Do not get pregnant while you are taking this medicine.

IMBRUVICA should not be used during pregnancy. There is no information about the safety of IMBRUVICA in pregnant women.

Women of childbearing age must use a highly effective method of birth control during and up to three months after receiving IMBRUVICA, to avoid

becoming pregnant while being treated with IMBRUVICA.

- Tell your doctor immediately if you become pregnant.
- Do not breast-feed while you are taking this medicine.

- Things to be careful of *IMBRUVICA with food*

Do not take IMBRUVICA with grapefruit or Seville oranges (bitter oranges) – this includes eating them, drinking the juice or taking a supplement that might contain them. This is because it can increase the amount of IMBRUVICA in your blood.

Driving and using machines

You may feel tired or dizzy after taking IMBRUVICA, which may affect your ability to drive or use any tools or machines.

Side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

The following side effects may happen with this medicine:

Stop taking IMBRUVICA and tell a doctor straight away if you notice any of the following side effects: itchy bumpy rash, difficulty breathing, swelling of your face, lips, tongue or throat – you may be having an allergic reaction to the medicine.

Tell a doctor straight away if you notice any of the following side effects:

Very common (may affect more than 1 in 10 people)

- fever, chills, body aches, feeling tired, cold or flu symptoms, being short of breath – these could be signs of an infection (viral, bacterial or fungal). These could include infections of the nose, sinus or throat (upper respiratory tract infection), or lung, or skin
- bruising or increased tendency of bruising
- mouth sores

- feeling dizzy
- headache
- constipation
- feeling or being sick (nausea or vomiting)
- indigestion
- diarrhoea, your doctor may need to give you a fluid and salt replacement or another medicine
- skin rash
- painful arms or legs
- back pain or joint pain
- muscle cramps, aches or spasms
- low number of cells that help blood clot (platelets), very low number of white blood cells shown in blood tests
- an increase in the number or proportion of white blood cells shown in blood tests
- swollen hands, ankles or feet
- high blood pressure
- increased level of “creatinine” in the blood

Common (may affect up to 1 in 10 people)

- severe infections throughout the body (sepsis)
- infections of the urinary tract
- nose bleeds, small red or purple spots caused by bleeding under the skin
- blood in your stomach, gut, stools or urine, heavier periods, or bleeding that you cannot stop from an injury
- heart failure
- missed heart beats, weak or uneven pulse, lightheadedness, shortness of breath, chest discomfort (symptoms of heart rhythm problems)
- low white blood cell counts with fever (febrile neutropenia)
- non-melanoma skin cancer, most frequently squamous cell and basal cell skin cancer
- blurred vision
- redness of the skin
- inflammation within the lungs that may lead to permanent damage

IMBRUVICA™

Ibrutinib (140 mg), capsules

Ibrutinib (140 mg, 280 mg, 420 mg) film-coated tablets

- high level of “uric acid” in the blood (shown in blood tests), which may cause gout
- breaking of the nails
- sudden kidney damage
- weakness, numbness, tingling or pain in your hands or feet or other parts of the body (peripheral neuropathy)

Uncommon (may affect up to 1 in 100 people)

- liver failure, including events with fatal outcome
- severe fungal infections
- confusion, headache with slurred speech or feeling faint – these could be signs of serious internal bleeding in your brain
- unusual levels of chemicals in the blood caused by the fast breakdown of cancer cells have happened during treatment of cancer and sometimes even without treatment (tumour lysis syndrome)
- allergic reaction, sometimes severe, that may include a swollen face, lip, mouth, tongue or throat, difficulty swallowing or breathing, itchy rash (hives)
- inflammation of the fatty tissue underneath the skin
- temporary episode of decreased brain or nerve function caused by loss of blood flow, stroke
- bleeding in the eye (in some cases associated with loss of vision)
- inflammation inside the eye that may affect vision (uveitis)
- cardiac arrest (heart stops beating)
- abnormally fast heart beat
- painful skin ulceration (pyoderma gangrenosum) or red, raised painful patches on the skin, fever and an increase in white blood cells (these may be signs of acute febrile neutrophilic dermatosis or Sweet’s syndrome)
- small, red bump on the skin that may bleed easily (pyogenic granuloma)

- inflamed blood vessels in the skin, which may lead to a rash (cutaneous vasculitis).

Rare (may affect up to 1 in 1,000 people)

- severely increased white blood cell count that may cause cells to clump together.
- severe rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (Stevens-Johnson syndrome).

You may report any side effects or adverse drug reactions directly to the National Centre for Adverse Drug Reaction Monitoring by visiting the website npra.gov.my [Consumers → Reporting Side Effects to Medicines (ConSERF) or Vaccines (AEFI)].

Storage and Disposal of IMBRUVICA

- **Storage**
Store below 30°C.

Keep out of reach of children.

Do not use this medicine after the expiry date which is stated on the carton and bottle label after EXP. The expiry date refers to the last day of that month.

This medicine does not require any special storage conditions.

- **Disposal**

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

Product description**Capsules**

- **What it looks like**

IMBRUVICA are white opaque, hard capsules marked with “ibr 140 mg” in black ink on one side.

The capsules are provided in a plastic bottle with a child resistant

polypropylene closure. Each bottle contains either 90 or 120 capsules. Each pack contains one bottle.

- **Ingredients**

Active ingredient
Ibrutinib

Inactive ingredients

- capsule content: croscarmellose sodium, magnesium stearate, microcrystalline cellulose and sodium lauril sulfate (E487)
- capsule shell: gelatin and titanium dioxide (E171)
- printing ink: shellac, iron oxide black (E172), and propylene glycol (E1520).

- **MAL number**

MAL16025029ACRZ
MAL19056121ASZ

Tablets

- **What it looks like**

IMBRUVICA 140 mg film-coated tablets: Yellow-green to green round (9 mm) tablets, written with “ibr” on one side and “140” on the other side.

IMBRUVICA 280 mg film-coated tablets: Purple oblong (15 mm in length and 7 mm in width), written with “ibr” on one side and “280” on the other side.

IMBRUVICA 420 mg film-coated tablets: Yellow-green to green oblong tablets (17.5 mm in length and 7.4 mm in width), written in “ibr” on one side and “420” on the other side.

Each 30-day carton contains 30 film-coated tablets in 3 cardboard wallets of 10 film-coated tablets each.

- **Ingredients**

Active ingredient
Ibrutinib

Inactive ingredients

- Tablet core: colloidal anhydrous silica, croscarmellose sodium, lactose monohydrate, Magnesium stearate,

IMBRUVICA™

Ibrutinib (140 mg), capsules

Ibrutinib (140 mg, 280 mg, 420 mg) film-coated tablets

microcrystalline cellulose,
povidone, sodium lauryl
sulfate (E487).

- Tablet film-coat: polyvinyl
alcohol, macrogol, talc,
titanium dioxide (E171);

IMBRUVICA 140 mg and
IMBRUVICA 420 mg film-
coated tablets also contain
black iron oxide (E172) and
yellow iron oxide (E172);

IMBRUVICA 280 mg film-
coated tablets also contain
black iron oxide (E172) and
red iron oxide (E172).

- *MAL number*

140mg: MAL22106001ARZ

280mg: MAL22106002ARZ

420mg: MAL22106003ARZ

Manufacturer

Capsules

Catalent CTS, LLC
10245 Hickman Mills Drive
Kansas City, MO
64137 USA

Cilag AG
Hochstrasse 201
Schaffhausen, 8200
Switzerland

Film-coated tablets

Cilag AG
Hochstrasse 201
Schaffhausen, 8200
Switzerland

Product Registration Holder

Johnson & Johnson Sdn Bhd (3718-D)
Level 8, The Pinnacle,
Persiaran Lagoon, Bandar Sunway,
46150, Petaling Jaya, Selangor,
Malaysia

Date of revision

23/09/2025 (MY PI based on EU
SmPC v16Sep2025)

Serial number

NPRA (R1/10) 11112024/202
NPRA (R1/AI7)21032024/005
